Targeting the mTOR signaling network for cancer therapy

Journal of Clinical Oncology

Volumn 27, Issue 13, 2009, Pages 2278-2287

  Meric Bernstam, Funda ^a   Gonzalez Angulo, Ana Maria ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 3' FLUOROTHYMIDINE F 18; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DEFOROLIMUS; DOXORUBICIN; EVEROLIMUS; EX 147; EX147; FLUORODEOXYGLUCOSE F 18; FULVESTRANT; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; OCTREOTIDE; PACLITAXEL; PIPENDOXIFENE; PLACEBO; RALOXIFENE; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CELL TYPE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ENDOMETRIUM CANCER; ENZYME INHIBITION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; NEOPLASM; PATIENT SELECTION; PHYSIOLOGY;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PATIENT SELECTION; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 65549167833     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.0766     Document Type: Review

References (116)

1. Zhou BP, Hu MC, Miller SA, et al: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027-8031, 2000
2. Chung J, Bachelder RE, Lipscomb EA, et al: Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: A survival mechanism for carcinoma cells. J Cell Biol 158:165-174, 2002 (Pubitemid 34886730)
3. Cui X, Zhang P, Deng W, et al: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588, 2003 (Pubitemid 36403572)
4. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091, 2008
5. Liaw D, Marsh DJ, Li J, et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67, 1997 (Pubitemid 27198157)
6. Shaw RJ, Bardeesy N, Manning BD, et al: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99, 2004 (Pubitemid 38903165)
7. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590, 2003 (Pubitemid 37506046)
8. Johannessen CM, Reczek EE, James MF, et al: The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102: 8573-8578, 2005
9. De Benedetti A, Graff JR: EIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189-3199, 2004 (Pubitemid 38638830)
10. Soni A, Akcakanat A, Singh G, et al: EIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782-1788, 2008
11. Culjkovic B, Topisirovic I, Skrabanek L, et al: EIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR. J Cell Biol 169:245-256, 2005 (Pubitemid 40656563)
12. Jastrzebski K, Hannan KM, Tchoubrieva EB, et al: Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 25:209-226, 2007
13. Nakamura JL, Garcia E, Pieper RO: S6K1 plays a key role in glial transformation. Cancer Res 68:6516-6523, 2008
14. Bärlund M, Forozan F, Kononen J, et al: Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92:1252-1259, 2000 (Pubitemid 30627733)
15. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006 (Pubitemid 43050086)
16. Phung TL, Ziv K, Dabydeen D, et al: Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10:159-170, 2006 (Pubitemid 44175906)
17. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 124:471-484, 2006
18. Wang L, Harris TE, Lawrence JC Jr: Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem 283:15619-15627, 2008
19. Jacinto E, Facchinetti V, Liu D, et al: SIN1/ MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137, 2006 (Pubitemid 44466632)
20. Yang Q, Inoki K, Ikenoue T, et al: Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20:2820-2832, 2006 (Pubitemid 44771744)
21. Pearce LR, Huang X, Boudeau J, et al: Identification of protor as a novel rictor-binding component of mTOR complex-2. Biochem J 405:513-522, 2007 (Pubitemid 47172049)
22. Frias MA, Thoreen CC, Jaffe JD, et al: MSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16:1865-1870, 2006
23. Martin J, Masri J, Bernath A, et al: Hsp70 associates with rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun 372:578-583, 2008
24. Sarbassov DD, Ali SM, Kim DH, et al: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302, 2004
25. Hresko RC, Mueckler M: MTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406-40416, 2005
26. McDonald PC, Oloumi A, Mills J, et al: Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68:1618-1624, 2008
27. Hernández-Negrete I, Carretero-Ortega J, Rosenfeldt H, et al: P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem 282:23708-23715, 2007 (Pubitemid 47311970)
28. Inoki K, Li Y, Zhu T, et al: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657, 2002 (Pubitemid 34993700)
29. Manning BD, Tee AR, Logsdon MN, et al: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151-162, 2002 (Pubitemid 34876569)
30. Potter CJ, Pedraza LG, Xu T: Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4:658-665, 2002
31. Roux PP, Ballif BA, Anjum R, et al: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 101:13489-13494, 2004 (Pubitemid 39238430)
32. Nobukuni T, Joaquin M, Roccio M, et al: Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 102:14238-14243, 2005 (Pubitemid 41429682)
33. Akcakanat A, Singh G, Hung MC, et al: Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun 362:330-333, 2007
34. Zeng Z, Sarbassov dos D, Samudio IJ, et al: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109:3509-3512, 2007
35. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006 (Pubitemid 43259931)
36. Shi Y, Yan H, Frost P, et al: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4:1533-1540, 2005 (Pubitemid 41556435)
37. Stoeltzing O, Meric-Bernstam F, Ellis LM: Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell 10:89-91, 2006 (Pubitemid 44175909)
38. Sarbassov DD, Ali SM, Sengupta S, et al: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159-168, 2006
39. Hidalgo M, Buckner JC, Erlichman C, et al: A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12:5755-5763, 2006 (Pubitemid 44629606)
40. Yee KW, Zeng Z, Konopleva M, et al: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5165-5173, 2006 (Pubitemid 44453345)
41. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004 (Pubitemid 41103603)
42. Chan S, Scheulen ME, Johnston S, et al: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314-5322, 2005 (Pubitemid 46206985)
43. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
44. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
45. Ansell SM, Inwards DJ, Rowland KM Jr, et al: Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group. Cancer 113:508-514, 2008
46. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle-cell lymphoma. J Clin Oncol 23: 5347-5356, 2005 (Pubitemid 46206988)
47. Smith SM, Pro B, Cisneros A, et al: Activity of single agent temsirolimus (CCI-779) in non- mantle-cell non-Hodgkin lymphoma subtypes. J Clin Oncol 26:457s, 2008 (suppl; abstr 8514)
48. Hess G, Romaguera JE, Verhoef G, et al: Phase III study of patients with relapsed, refractory mantle-cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J Clin Oncol 26:457s, 2008 (suppl; abstr 8513)
49. Stallone G, Schena A, Infante B, et al: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352:1317-1323, 2005 (Pubitemid 40411498)
50. Chawla SP, Tolcher AW, Staddon AP, et al: Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol 24:521s, 2006 (suppl; abstr 9505)
51. Colombo N, McMeekin S, Schwartz P, et al: A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 25:278s, 2007 (suppl; abstr 5516)
52. Herry I, Neukirch C, Debray MP, et al: Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 18:76-77, 2007 (Pubitemid 46091655)
53. Bissler JJ, McCormack FX, Young LR, et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151, 2008
54. Wienecke R, Fackler I, Linsenmaier U, et al: Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 48:e27-e29, 2006 (Pubitemid 44262422)
55. Mondesire WH, Jian W, Zhang H, et al: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10:7031-7042, 2004 (Pubitemid 39383055)
56. Podsypanina K, Lee RT, Politis C, et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001 (Pubitemid 32803018)
57. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001 (Pubitemid 32803017)
58. Shi Y, Gera J, Hu L, et al: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027-5034, 2002 (Pubitemid 34984430)
59. Steelman LS, Navolanic PM, Sokolosky ML, et al: Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27:4086-4095, 2008
60. DeGraffenried LA, Fulcher L, Friedrichs WE, et al: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15:1510-1516, 2004 (Pubitemid 39409742)
61. Baselga J, van Dam PA, Greil R, et al: Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer. J Clin Oncol 26:13s, 2008 (suppl; abstr 530)
62. Slomovitz BM, Lu KH, Johnston T, et al: A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus) in patients with recurrent endometrial carcinoma (EC). J Clin Oncol 26:293s, 2008 (suppl; abstr 5502)
63. Noh WC, Mondesire WH, Peng J, et al: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013-1023, 2004 (Pubitemid 38198903)
64. Bader AG, Kang S, Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103:1475-1479, 2006 (Pubitemid 43191190)
65. Cho D, Signoretti S, Dabora S, et al: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379-385, 2007 (Pubitemid 47584475)
66. Iwenofu OH, Lackman RD, Staddon AP, et al: Phospho-S6 ribosomal protein: A potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21:231-237, 2008
67. Duran I, Kortmansky J, Singh D, et al: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154, 2006 (Pubitemid 44660065)
68. Baker AF, Dragovich T, Ihle NT, et al: Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11:4338-4340, 2005 (Pubitemid 40825621)
69. Akcakanat A, Sahin A, Shaye AN, et al: Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112:2352-2358, 2008
70. Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003 (Pubitemid 36993245)
71. Boulay A, Zumstein-Mecker S, Stephan C, et al: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261, 2004 (Pubitemid 38114106)
72. Tanaka C, O'Reilly T, Kovarik JM, et al: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602, 2008
73. O'Donnell A, Faivre S, Burris HA III, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595, 2008
74. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
75. Yu K, Toral-Barza L, Discafani C, et al: mTOR, a novel target in breast cancer: The effect of CCI- 779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258, 2001 (Pubitemid 32947647)
76. Dudkin L, Dilling MB, Cheshire PJ, et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764, 2001 (Pubitemid 32708646)
77. Graff JR, Konicek BW, Vincent TM, et al: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638-2648, 2007
78. Wendel HG, De Stanchina E, Fridman JS, et al: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332-337, 2004 (Pubitemid 38418805)
79. Carracedo A, Ma L, Teruya-Feldstein J, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065-3074, 2008
80. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al: Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8, 2008
81. Gera JF, Mellinghoff IK, Shi Y, et al: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279:2737-2746, 2004 (Pubitemid 38114263)
82. Law M, Forrester E, Chytil A, et al: Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 66:1070-1080, 2006 (Pubitemid 43165975)
83. Dong J, Peng J, Zhang H, et al: Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65:1961-1972, 2005
84. Wei LH, Su H, Hildebrandt IJ, et al: Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 14:3416-3426, 2008
85. Shor B, Zhang WG, Toral-Barza L, et al: A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68:2934-2943, 2008 (Pubitemid 351556294)
86. Pandya KJ, Dahlberg S, Hidalgo M, et al: A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2:1036-1041, 2007 (Pubitemid 350059580)
87. Grünwald V, DeGraffenried L, Russel D, et al: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62:6141-6145, 2002 (Pubitemid 35244463)
88. Geoerger B, Kerr K, Tang CB, et al: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527-1532, 2001 (Pubitemid 34292583)
89. Beuvink I, Boulay A, Fumagalli S, et al: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120:747-759, 2005 (Pubitemid 40568794)
90. Wan X, Harkavy B, Shen N, et al: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007
91. Yao JC, Phan AT, Chang DZ, et al: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 26:4311-4318, 2008
92. Charland S, Boucher MJ, Houde M, et al: Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 142:121-128, 2001 (Pubitemid 32183673)
93. Moreno A, Akcakanat A, Munsell MF, et al: Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15:257-266, 2008
94. Lu CH, Wyszomierski SL, Tseng LM, et al: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13:5883-5888, 2007
95. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004 (Pubitemid 39485684)
96. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007 (Pubitemid 47539306)
97. André F, Campone M, Hurvitz SA, et al: Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 26:41s, 2008 (suppl; abstr 1003)
98. Pérez-Tenorio G, Stal O: Activation of AKT/ PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545, 2002 (Pubitemid 34185089)
99. Sadler TM, Gavriil M, Annable T, et al: Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer 13:863-873, 2006 (Pubitemid 44763262)
100. Beeram M, Tan QT, Tekmal RR, et al: Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18:1323-1328, 2007 (Pubitemid 47305004)
101. deGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059-8067, 2004
102. Chow LWC, Sun Y, Jassem J, et al: Phase III study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Presented at the 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, TX
103. Awada A, Cardoso F, Fontaine C, et al: The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 44:84-91, 2008 (Pubitemid 350256937)
104. Dowling RJ, Zakikhani M, Fantus IG, et al: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812, 2007 (Pubitemid 350145909)
105. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304, 2005 (Pubitemid 46206983)
106. Margolin K, Longmate J, Baratta T, et al: CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Cancer 104:1045-1048, 2005 (Pubitemid 41170233)
107. Rizzieri DA, Feldman E, Dipersio JF, et al: A phase II clinical trial of deforolimus (AP23573, MK- 8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14: 2756-2762, 2008
108. Gingras AC, Gygi SP, Raught B, et al: Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 13:1422-1437, 1999 (Pubitemid 29270247)
109. Gingras AC, Raught B, Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 15:807-826, 2001
110. Raught B, Gingras AC, Gygi SP, et al: Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. Embo J 19:434-444, 2000 (Pubitemid 30072613)
111. Ramírez-Valle F, Braunstein S, Zavadil J, et al: EIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 181:293-307, 2008 (Pubitemid 351574554)
112. Raught B, Peiretti F, Gingras AC, et al: Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. Embo J 23:1761-1769, 2004 (Pubitemid 38649639)
113. Hong F, Larrea MD, Doughty C, et al: MTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30:701-711, 2008 (Pubitemid 351815130)
114. Huang S, Shu L, Dilling MB, et al: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 11:1491-1501, 2003 (Pubitemid 36776536)
115. Hashemolhosseini S, Nagamine Y, Morley SJ, et al: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273:14424-14429, 1998 (Pubitemid 28319162)
116. Bermudez O, Marchetti S, Pages G, et al: Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. Oncogene 27:3685-3691, 2008 (Pubitemid 351912973)